BTF3P6

Across TCGA pan-cancer cohorts, BTF3P6 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of BTF3P6’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where BTF3P6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BTF3P6 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

BLCA, KIRC, and STAD are the cancer types where BTF3P6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTF3P6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.168	.013	6	view →
KIRC	All	II,III,IV	+0.055	.006	5	view →
STAD	All	All	+0.201	.011	4	view →
COAD	All	All	+0.159	.002	4	view →
LUSC	Male	All	+0.155	<.001	4	view →
THCA	All	All	−0.066	.005	2	view →
READ	All	All	+0.220	.041	1	view →
CHOL	All	All	+0.175	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

BTF3P6–BLCA

Open the BLCA breakdown →